Shanghai Pudong: By 2027, striving to break through the scale of the biopharmaceutical industry to over 500 billion yuan.

The People's Government Office of Pudong New Area, Shanghai issued the "Functional Enhancement Plan for Pudong New Area Biomedical Industry Park". It proposes to benchmark international first-class standards, adhere to the dual drive of scientific and technological innovation and institutional innovation, insist on the equal importance of research and development and manufacturing, continuously improve the innovation and entrepreneurship ecosystem, focus on the Zhangjiang Science City and Waigaoqiao area, form a linkage pattern of innovative core areas, industrial carrier areas, and industrial linkage areas with the development of "1+1+X", accelerate the construction of a world-class biomedical industry park with "element gathering, ecological integrity, complete supporting facilities, and vitality", and strive to create the global original pharmaceutical and medical device first release location, the preferred location for scientists to start businesses, and the pioneer in institutional reform. By 2027, the scale of the biomedical industry will exceed 500 billion yuan, with industrial output value exceeding 100 billion yuan, and the proportion of innovative pharmaceutical and medical device output value reaching 35-40%; more than 15 innovative class 1 new drugs will be approved in three years, 2-4 innovative drugs with new mechanisms and new targets, and global first-release products will double; cultivate 1-2 innovative pharmaceutical companies with a market value of over 10 billion yuan, add 1-2 single products with a market value of over 5 billion yuan; more than 10 domestic innovative medical device products will enter the international mainstream market.